.svg){kind=small}
Authors: Pierpaolo Pellicori MD, John G.F. Cleland MD, PhD, Maria Borentain MD, Jorg Taubel MD, Fraser Graham MB ChB, Javed Khan MB ChB, Dario Bruzzese PhD, Paul Kessler MD, John J.V. McMurray MD, Adriaan A. Voors MD, PhD, Christopher M. O'Connor MD, John R. Teerlink MD, G. Michael Felker MD, MHSIn a recent publication in the European Journal of Heart Failure (November 2023), the impact of cimlanod, a vasodilator, on diuretic response in congestive heart failure patients is explored. Download
.avif)
Latest news
Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology
December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
